[F:1][C:2]([F:12])([F:11])[C:3]1[C:7]([CH2:8][CH2:9][OH:10])=[CH:6][NH:5][N:4]=1.Cl[CH2:14][C:15]1[NH:16][C:17](=[O:25])[C:18]2[CH:23]=[C:22]([CH3:24])[S:21][C:19]=2[N:20]=1.CC(C)([O-])C.[K+]>C1COCC1>[OH:10][CH2:9][CH2:8][C:7]1[C:3]([C:2]([F:1])([F:11])[F:12])=[N:4][N:5]([CH2:14][C:15]2[NH:16][C:17](=[O:25])[C:18]3[CH:23]=[C:22]([CH3:24])[S:21][C:19]=3[N:20]=2)[CH:6]=1A mixture of 2-(3-(trifluoromethyl)-1H-pyrazol-4-yl)ethanol (50 mg, 0.278 mmol), 2-(chloromethyl)-6-methylthieno[2,3-d]pyrimidin-4(3H)-one (60 mg, 0.278 mmol) and potassium tert-butoxide (62 mg, 0.07 mL, 0.555 mmol) in THF (3 mL) was heated to 75° C. for 4 h. The reaction mixture was allowed to cool to RT before being filtered and concentrated in vacuo. The residue was purified by preparative reverse phase HPLC to give the title compound as a white solid (32 mg, 0.089 mmol, 32%).